300 related articles for article (PubMed ID: 31230012)
1. One- and two-year visual outcomes from the Moorfields age-related macular degeneration database: a retrospective cohort study and an open science resource.
Fasler K; Moraes G; Wagner S; Kortuem KU; Chopra R; Faes L; Preston G; Pontikos N; Fu DJ; Patel P; Tufail A; Lee AY; Balaskas K; Keane PA
BMJ Open; 2019 Jun; 9(6):e027441. PubMed ID: 31230012
[TBL] [Abstract][Full Text] [Related]
2. Evolving Treatment Patterns and Outcomes of Neovascular Age-Related Macular Degeneration Over a Decade.
Schwartz R; Warwick A; Olvera-Barrios A; Pikoula M; Lee AY; Denaxas S; Taylor P; Egan C; Chakravarthy U; Lip PL; Tufail A;
Ophthalmol Retina; 2021 Aug; 5(8):e11-e22. PubMed ID: 33866023
[TBL] [Abstract][Full Text] [Related]
3. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
[TBL] [Abstract][Full Text] [Related]
4. UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice.
Lee AY; Lee CS; Egan CA; Bailey C; Johnston RL; Natha S; Hamilton R; Khan R; Al-Husainy S; Brand C; Akerele T; Mckibbin M; Downey L; Tufail A
Br J Ophthalmol; 2017 Dec; 101(12):1683-1688. PubMed ID: 28478396
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence.
Chakravarthy U; Bezlyak V; Sagkriotis A; Griner R; Skelly A; Boyer DS; Milnes F
Ophthalmol Retina; 2019 Jan; 3(1):8-15.e1. PubMed ID: 30929819
[TBL] [Abstract][Full Text] [Related]
6. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity.
Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group
Ophthalmology; 2014 May; 121(5):1092-101. PubMed ID: 24461586
[TBL] [Abstract][Full Text] [Related]
7. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
Lanzetta P; Cruess AF; Cohen SY; Slakter JS; Katz T; Sowade O; Zeitz O; Ahlers C; Mitchell P
Acta Ophthalmol; 2018 Dec; 96(8):e911-e918. PubMed ID: 29659183
[TBL] [Abstract][Full Text] [Related]
8. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
[TBL] [Abstract][Full Text] [Related]
9. Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration.
Fasler K; Fu DJ; Moraes G; Wagner S; Gokhale E; Kortuem K; Chopra R; Faes L; Preston G; Pontikos N; Patel PJ; Tufail A; Lee AY; Balaskas K; Keane PA
Br J Ophthalmol; 2020 May; 104(5):684-690. PubMed ID: 31611234
[TBL] [Abstract][Full Text] [Related]
10. Impact of injection frequency on 5-year real-world visual acuity outcomes of aflibercept therapy for neovascular age-related macular degeneration.
Chandra S; Rasheed R; Menon D; Patrao N; Lamin A; Gurudas S; Balaskas K; Patel PJ; Ali N; Sivaprasad S
Eye (Lond); 2021 Feb; 35(2):409-417. PubMed ID: 32265509
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
Peden MC; Suñer IJ; Hammer ME; Grizzard WS
Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
[TBL] [Abstract][Full Text] [Related]
12. First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration.
Talks JS; Lotery AJ; Ghanchi F; Sivaprasad S; Johnston RL; Patel N; McKibbin M; Bailey C; Mahmood S;
Ophthalmology; 2016 Feb; 123(2):337-343. PubMed ID: 26578446
[TBL] [Abstract][Full Text] [Related]
13. UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV: Incidence of Blindness and Sight Impairment in Ranibizumab-Treated Patients.
Johnston RL; Lee AY; Buckle M; Antcliff R; Bailey C; McKibbin M; Chakravarthy U; Tufail A;
Ophthalmology; 2016 Nov; 123(11):2386-2392. PubMed ID: 27615601
[TBL] [Abstract][Full Text] [Related]
14. SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States.
Khanani AM; Skelly A; Bezlyak V; Griner R; Torres LR; Sagkriotis A
Ophthalmol Retina; 2020 Feb; 4(2):122-133. PubMed ID: 31812631
[TBL] [Abstract][Full Text] [Related]
15. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.
Barthelmes D; Campain A; Nguyen P; Arnold JJ; McAllister IL; Simpson JM; Hunyor AP; Guymer R; Essex RW; Morlet N; Gillies MC;
Br J Ophthalmol; 2016 Dec; 100(12):1640-1645. PubMed ID: 26994110
[TBL] [Abstract][Full Text] [Related]
16. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes.
Ciulla TA; Hussain RM; Pollack JS; Williams DF
Ophthalmol Retina; 2020 Jan; 4(1):19-30. PubMed ID: 31324588
[TBL] [Abstract][Full Text] [Related]
17. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set.
Lotery A; Griner R; Ferreira A; Milnes F; Dugel P
Eye (Lond); 2017 Dec; 31(12):1697-1706. PubMed ID: 28731052
[TBL] [Abstract][Full Text] [Related]
18. Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age-related macular degeneration: data from the INSIGHT study using the Swedish Macula Register.
Lövestam Adrian M; Vassilev ZP; Westborg I
Acta Ophthalmol; 2019 Feb; 97(1):91-98. PubMed ID: 30238648
[TBL] [Abstract][Full Text] [Related]
19. [Real life visual and anatomic outcomes of aflibercept treatment for treatment-naive patients with exudative age-related macular degeneration].
Duval MV; Rougier MB; Delyfer MN; Combillet F; Korobelnik JF
J Fr Ophtalmol; 2017 Apr; 40(4):270-278. PubMed ID: 28341388
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
